{"title":"New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer","authors":"Kévin Hébert , Paul Bodin-Cufi , Cyril Fersing , Emmanuel Deshayes","doi":"10.1016/j.euf.2024.07.016","DOIUrl":null,"url":null,"abstract":"<div><div>Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [<sup>177</sup>Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters.</div></div><div><h3>Patient summary</h3><div>Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.</div></div>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":"10 4","pages":"Pages 514-517"},"PeriodicalIF":4.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405456924001548","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters.
Patient summary
Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.
转移性前列腺癌是一种常见的致命疾病。自[177Lu]Lu-PSMA-617获批以来，靶向放射性核素治疗（TRT）已成为一种现成的治疗方法。目前正在研究用于前列腺癌 TRT 的各种分子。我们回顾了用于靶向前列腺癌细胞和优化药代动力学的同位素和载体的各种组合。有前景的创新包括改善生物分布的化学修饰、新靶点的确定以及新型放射性同位素（如α发射体）的使用。患者摘要：我们的微型综述总结了治疗转移性前列腺癌的靶向放射性药物研究。目前正在对几种前景看好的放射性药物进行临床试验评估，但在将这些药物用于常规临床实践之前，还需要进行更多的研究。
期刊介绍：
European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU).
EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
